Skip to Main Content

Paper Details

Genomic landscape of TP53-mutated myeloid malignancies.
Blood Adv
8
2023
AML, AMLs, ETV6, MDS, NF1, TP53, TP53 allele, TP53-, TP53-mutated, TP53-mutated AML, TP53-mutated AML/, TP53-mutated cancers, TP53-mutated myeloid malignancies, abnormal telomeric sequences, acute myeloid leukemia, aneuploidy, cancer, chromosome, chromosomes, chromothripsis, myelodysplastic syndromes, myeloid malignancies, normal tissue, telomere, unique genes
Author NameAffiliation
Christopher A MillerWashington University School of Medicine
Catrina FronickMcDonnell Genome Institute, Washington University School of Medicine
Robert S FultonMcDonnell Genome Institute, Washington University School of Medicine
Robert S FultonMcDonnell Genome Institute, Washington University School of Medicine
Sharon E HeathWashington University School of Medicine
Jacqueline E PaytonWashington University School of Medicine
David H SpencerWashington University School of Medicine
David H SpencerMcDonnell Genome Institute, Washington University School of Medicine
David H SpencerWashington University School of Medicine
Matthew J WalterWashington University School of Medicine
Peter WesterveltWashington University School of Medicine
John F DiPersioWashington University School of Medicine
Timothy J LeyWashington University School of Medicine
Daniel C LinkWashington University School of Medicine
  • 1 - 14

Datasets

Release 1.2